Stoke Therapeutics (STOK) Common Equity (2018 - 2026)

Stoke Therapeutics' Common Equity history runs 9 years deep, the most recent figure standing at $394.9 million for Q1 2026.

• In Q1 2026, Common Equity rose 12.8% year-over-year to $394.9 million; the TTM figure through Mar 2026 stood at $394.9 million (up 12.8% YoY), while the FY2025 annual figure was $352.5 million, up 53.9% from the prior year.
• Common Equity was $394.9 million for Q1 2026 at Stoke Therapeutics, up from $352.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $394.9 million in Q1 2026 to a low of $140.3 million in Q1 2024.
• Historically, Common Equity has averaged $245.6 million across 5 years, with a median of $229.0 million in 2024.
• The sharpest annual moves came in 2024 and 2025: Common Equity slumped 34.37% in 2024, then jumped 149.44% in 2025.
• A 5-year view of Common Equity shows it stood at $184.8 million in 2022, then retreated by 13.68% to $159.6 million in 2023, then surged by 43.53% to $229.0 million in 2024, then surged by 53.9% to $352.5 million in 2025, then advanced by 12.04% to $394.9 million in 2026.
• The last three Common Equity figures came in at $394.9 million (Q1 2026), $352.5 million (Q4 2025), and $308.1 million (Q3 2025), per Business Quant data.